Custo da resposta virológica com dois medicamentos ativos na terapia de suporte otimizada com etravirina, raltegravir e maraviroc no Programa Nacional de AIDS do Brasil
Custo da resposta virológica com dois medicamentos ativos na terapia de suporte otimizada com etravirina, raltegravir e maraviroc no Programa Nacional de AIDS do Brasil
Tipo de documento
Apresentação
Descrição
Resumo apresentado na The Professional Society for Health Economics and Outcomes Research (ISPOR)
Fonte
ISPOR
Ano de publicação
2011
Referência (Vancouver)
Morais AD, Pereira ML, Azevedo H. Cost of virologic response with two active drugs in the optimized background therapy with etravirine, raltegravir, and maraviroc in the Brazilian national aids program [Internet]. In: ISPOR Europe 2011; Madrid, Spain. Disponível em: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-14th-annual-european-congress/cost-of-virologic-response-with-two-active-drugs-in-the-optimized-background-therapy-with-etravirine-raltegravir-and-maraviroc-in-the-brazilian-national-aids-program
Cost of Virologic Response with Two Active Drugs in the Optimized Background Therapy with Etravirine, Raltegravir, and Maraviroc in the Brazilian National Aids Program.
Document type
Presentation
Description
Abstract presented at The Professional Society for Health Economics and Outcomes Research (ISPOR)
Source
ISPOR
Publication year
2011
Reference (Vancouver)
Morais AD, Pereira ML, Azevedo H. Cost of virologic response with two active drugs in the optimized background therapy with etravirine, raltegravir, and maraviroc in the Brazilian national aids program [Internet]. In: ISPOR Europe 2011; Madrid, Spain. Available from: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-14th-annual-european-congress/cost-of-virologic-response-with-two-active-drugs-in-the-optimized-background-therapy-with-etravirine-raltegravir-and-maraviroc-in-the-brazilian-national-aids-program
Objetivos: Estimar o custo da resposta virológica na semana 48 para pacientes com HIV multi-expostos tratados com etravirina (ETV), raltegravir (RAL) e maraviroc (MAV) com pelo menos 2 drogas ativas na Terapia de Fundo Otimizada (TFO) sob o Programa Nacional de AIDS do Brasil. Métodos: Regimes de tratamento para ETV e RAL foram definidos pelas diretrizes nacionais Brasileiras, enquanto os regimes com MAV seguiram princípios semelhantes, embora o MAV ainda não seja reembolsado. Pacientes que não atingiram resposta virológica foram trocados para tratamentos de resgate subsequentes conforme as diretrizes, sem permissão para re-tratamento. Os custos de tratamento incluíram os custos dos medicamentos publicados no site do governo, com o custo do MAV definido por lei. O número de pacientes multi-expostos recebendo tratamento foi estimado com base nas cápsulas dispensadas de RAL nos últimos 48 semanas. As taxas de resposta virológica foram obtidas de ensaios clínicos de fase III de ETV, MAV e RAL, avaliando os resultados na semana 48 para pacientes com duas drogas ativas na TFO com base na suscetibilidade fenotípica. Resultados: O custo médio de tratamento na semana 48 para pacientes multi-expostos com pelo menos 2 drogas ativas na TFO foi: - R$ 27.243,14 com ETV - R$ 27.702,91 com RAL - R$ 31.220,72 com MAV Com 5.627 pacientes multi-expostos recebendo tratamento, 862 pacientes falharam com MAV, 544 com RAL e 337 com ETV. Para um terço da coorte (1.875 pacientes), o custo total de tratamento foi: - R$ 58.565.276 para MAV - R$ 51.966.391 para RAL - R$ 51.103.946 para ETV Conclusões: Apesar dos custos semelhantes de tratamento, o tratamento com ETV comparado ao RAL e MAV é uma opção mais econômica para o tratamento de pacientes multi-expostos com pelo menos duas drogas ativas na TFO. Na semana 48, o tratamento com RAL e MAV foi em média 2% e 15% mais caro comparado ao ETV, respectivamente.
Notas
O registro foi originalmente publicado em inglês. A versão em português foi traduzida com o apoio de inteligência artificial.
Abstract
Objetives: To estimate the cost of virologic response at week 48 of treatment with etravirine (ETV), raltegravir (RAL) and maraviroc (MAV) for multi-experienced patients with 2 or more active drugs in the optimized Background therapy (OBT) in the Brazilian National AIDS Program. Methods: Treatment regimens of ETV and RAL were defined by the Brazilian national guidelines. Regimens with MAV were based in the same principles, although the drug is not yet reimbursed. Patients not achieving virologic response followed onto subsequent rescue treatments, defined by the guidelines. Re-treatment was not allowed. Treatment costs included cost of medication as published on the government website. The cost of MAV was defined by law. The number of multi-experienced patients receiving treatment was based on the dispensed capsules of RAL in the last 48 weeks. Virologic response was gathered from the phase III clinical trials of ETV, MAR and RAL, at week 48 for patients with two active drugs in the OBT defined by phenotypic susceptibility. Results: The average cost of treatment at week 48 for multi-experienced patients with at least 2 active drugs in the OBT was R$ 27,243.14 with ETV, compared with R$ 27,702.91 with RAL, and R$ 31,220.72 with MAR. Given 5,627 multi-experienced patients received treatment, 862 patients failed with MAV, 544 failed treatment with RAL compared to 337 failed patients with ETV. For one third of the cohort (1.875), the total cost of treatment was R$ 58,565,276 for MAV, R$ 51,966,391 for RAL, and R$ 51,103,946 for ETV. Conclusions: Despite similar treatment costs, treatment with ETV compared to RAL and MAV is a more economic option for the treatment of multi-experienced patients with at least two active drugs in the OBT. At week 48, treatment with RAL and MAV was on average 2% and 15% more expensive compared to ETV, respectively.
Notes
The record was originally published in English. The Portuguese version was translated with the aid of artificial intelligence.
